{"disease":{"id":"cold-autoimmune-hemolytic-anemia","name":"Cold autoimmune hemolytic anemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"sutimlimab","indication_name":"Cold autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enjaymo","generic_name":"SUTIMLIMAB","company_name":"Bioverativ Therapeutics Inc","drug_phase":"marketed","molecular_target":"Complement C1s subcomponent","drug_class":"Classical Complement Pathway Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Enjaymo works by blocking the activity of the complement C1s subcomponent, a part of the immune system that can mistakenly attack red blood cells."},{"drug_id":"sutimlimab-jome","indication_name":"Cold autoimmune hemolytic anemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ENJAYMO","generic_name":"SUTIMLIMAB-JOME","company_name":"RECORDATI RARE DISEASES, INC.","drug_phase":"marketed","molecular_target":"Complement C1s subcomponent","drug_class":"Classical Complement Pathway Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07019038","title":"National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia","phase":"","overall_status":"RECRUITING","enrollment_count":9999,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT02502903","title":"Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Bioverativ, a Sanofi company","has_results":false},{"nct_id":"NCT06847607","title":"A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Bing Han","has_results":false},{"nct_id":"NCT07091370","title":"Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Juventas Cell Therapy Ltd.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}